Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in pharma and consultancy business.[1]
- Market Cap ₹ 6.77 Cr.
- Current Price ₹ 6.70
- High / Low ₹ 12.0 / 5.00
- Stock P/E
- Book Value ₹ 20.5
- Dividend Yield 0.00 %
- ROCE -16.7 %
- ROE -14.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.33 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.0% over past five years.
- Promoter holding is low: 16.4%
- Company has a low return on equity of -6.51% over last 3 years.
- Working capital days have increased from 226 days to 395 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 14.05 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 17.44 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -3.39 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -24.13% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 0.22 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.52 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -3.69 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | -16.26% |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -3.08 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -3.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -24% |
| 3 Years: | -32% |
| TTM: | -38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1285% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -28% |
| 3 Years: | -28% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -7% |
| Last Year: | -14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 10.57 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.50 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 3.16 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 24.33 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.53 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.80 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 24.33 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | -9.82 | -2.08 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | 3.07 | -0.24 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | 0.24 | 0.26 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 | -6.51 | -2.07 |
| Free Cash Flow | -0.10 | 0.22 | -15.42 | 1.52 | 8.06 | -2.34 | 4.79 | -9.88 | -2.32 |
| CFO/OP | -143% | 51% | -602% | 53% | 137% | 37% | -713% | 520% | 61% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 | 67.54 |
| Inventory Days | 91.25 | 19.70 | 0.00 | ||||||
| Days Payable | 511.00 | 192.66 | |||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 | 67.54 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 | 395.40 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% | -16.67% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Consolidated IT Consulting Services Revenue Contribution INR Lakhs |
|
||||||
| Consolidated Pharma Revenue Contribution INR Lakhs |
|||||||
| Customer Concentration - Pharma Segment Revenue from Single Customer (Standalone) % ・Standalone data |
|||||||
| Median Remuneration of Employees (MRE) INR ・Standalone data |
|||||||
| Number of employees (Standalone) Number ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual secretarial compliance report for FY2026; details SEBI order, penalties on promoters, and SAT stay on company restriction.
- Audited Standalone And Consolidated Financial Results & Statements For The Quarter And Year Ended 31.03.2026 30 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2026
30 May - Board approved audited standalone and consolidated FY2026 results on 30 May 2026; auditors issued unmodified opinion.
-
Board Meeting Intimation for 1. Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended
March 31, 2026.
2. Audit Report (Standalone And Consolidated) For The Year Ended March 31, 2026.
3. Any Other Business With The Permission Of The Chair.
26 May - Board meeting on 30 May 2026 to consider audited Q4 and FY2026 financial results.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
22 Apr - Decipher Labs reports it is not a Large Corporate; FY26 borrowing nil.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
DCL is in the business of:
a) Pharma:
Manufacturing and trading of Pharmaceutical products
b) Consultancy:
It also provides consultancy services